Recurrent Ovarian Transitional Cell Carcinoma
specificThe reemergence of ovarian transitional cell carcinoma after a period of remission.
40
Centers
43
Active Trials
—
Cancer Funding
Top Centers for Recurrent Ovarian Transitional Cell Carcinoma(40)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive High-Volume Research Center | 72.1 |
| 2 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive High-Volume Research Center | 72.1 |
| 3 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive High-Volume Research Center | 72.1 |
| 4 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 49.6 |
| 5 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 49.6 |
| 6 | University of Michigan Rogel Cancer CenterAnn Arbor, MI NCI Comprehensive Active Research Program | 49.6 |
| 7 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive Active Research Program | 49.6 |
| 8 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 49.6 |
| 9 | NCI Comprehensive Active Research Program | 49.6 |
| 10 | NCI Comprehensive Active Research Program | 49.6 |
| 11 | NCI Comprehensive Active Research Program | 49.6 |
| 12 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 49.6 |
| 13 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 49.6 |
| 14 | NCI Comprehensive Active Research Program | 49.6 |
| 15 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 49.6 |
| 16 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive Active Research Program | 49.6 |
| 17 | Case Comprehensive Cancer CenterCleveland, OH NCI Comprehensive Active Research Program | 49.6 |
| 18 | UC Davis Comprehensive Cancer CenterSacramento, CA NCI Comprehensive Active Research Program | 49.6 |
| 19 | Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program | 49.6 |
| 20 | NCI Clinical Active Research Program | 49.6 |
| 21 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 49.6 |
| 22 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 49.6 |
| 23 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 49.6 |
| 24 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive Active Research Program | 49.6 |
| 25 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 49.6 |
| 26 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 49.6 |
| 27 | University of Illinois Cancer CenterChicago, IL Active Research Program | 49.6 |
| 28 | University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical Active Research Program | 49.6 |
| 29 | University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive Active Research Program | 49.6 |
| 30 | UAMS Winthrop P. Rockefeller Cancer InstituteLittle Rock, AR Active Research Program | 49.6 |
| 31 | Boston University Cancer CenterBoston, MA Active Research Program | 49.6 |
| 32 | Active Research Program | 49.6 |
| 33 | Cancer Center at IllinoisUrbana, IL Active Research Program | 49.6 |
| 34 | Penn State Cancer InstituteHershey, PA Active Research Program | 49.6 |
| 35 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 49.6 |
| 36 | Georgia Cancer Center, Augusta UniversityAugusta, GA Active Research Program | 49.6 |
| 37 | Active Research Program | 49.6 |
| 38 | Northwell Health Cancer InstituteNew York, NY Active Research Program | 49.6 |
| 39 | Upstate Cancer CenterSyracuse, NY Active Research Program | 49.6 |
| 40 | Louisiana Cancer Research CenterNew Orleans, LA Active Research Program | 49.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →